Last reviewed · How we verify

local dexmedetomidine

The University of Hong Kong · Phase 3 active Small molecule

local dexmedetomidine is a Alpha-2 adrenergic receptor agonist Small molecule drug developed by The University of Hong Kong. It is currently in Phase 3 development for Sedation for patients undergoing mechanical ventilation. Also known as: Precedex.

Local dexmedetomidine acts as an alpha-2 adrenergic receptor agonist to induce sedation and analgesia.

Local dexmedetomidine acts as an alpha-2 adrenergic receptor agonist to induce sedation and analgesia. Used for Sedation for patients undergoing mechanical ventilation.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namelocal dexmedetomidine
Also known asPrecedex
SponsorThe University of Hong Kong
Drug classAlpha-2 adrenergic receptor agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

By activating alpha-2 adrenergic receptors in the brain, local dexmedetomidine reduces the release of norepinephrine, leading to decreased sympathetic nervous system activity and subsequent sedative and analgesic effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about local dexmedetomidine

What is local dexmedetomidine?

local dexmedetomidine is a Alpha-2 adrenergic receptor agonist drug developed by The University of Hong Kong, indicated for Sedation for patients undergoing mechanical ventilation.

How does local dexmedetomidine work?

Local dexmedetomidine acts as an alpha-2 adrenergic receptor agonist to induce sedation and analgesia.

What is local dexmedetomidine used for?

local dexmedetomidine is indicated for Sedation for patients undergoing mechanical ventilation.

Who makes local dexmedetomidine?

local dexmedetomidine is developed by The University of Hong Kong (see full The University of Hong Kong pipeline at /company/the-university-of-hong-kong).

Is local dexmedetomidine also known as anything else?

local dexmedetomidine is also known as Precedex.

What drug class is local dexmedetomidine in?

local dexmedetomidine belongs to the Alpha-2 adrenergic receptor agonist class. See all Alpha-2 adrenergic receptor agonist drugs at /class/alpha-2-adrenergic-receptor-agonist.

What development phase is local dexmedetomidine in?

local dexmedetomidine is in Phase 3.

What are the side effects of local dexmedetomidine?

Common side effects of local dexmedetomidine include Hypotension, Bradycardia, Dry mouth.

What does local dexmedetomidine target?

local dexmedetomidine targets Alpha-2 adrenergic receptor and is a Alpha-2 adrenergic receptor agonist.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing